Preparation and biological evaluation of 1'-cyano-2'-C-methyl pyrimidine nucleosides as HCV NS5B polymerase inhibitors.

[1]  W. Zhong,et al.  Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients. , 2014, Journal of medicinal chemistry.

[2]  M. Manns,et al.  Novel therapies for hepatitis C — one pill fits all? , 2013, Nature Reviews Drug Discovery.

[3]  B. Kronenberger,et al.  New developments in HCV therapy , 2012, Journal of viral hepatitis.

[4]  M. Sofia.  Nucleotide Prodrugs for HCV Therapy , 2011, Antiviral chemistry & chemotherapy.

[5]  M. Otto,et al.  Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. , 2010, Journal of medicinal chemistry.

[6]  W. Stec,et al.  An efficient and diastereoselective synthesis of PSI-6130: a clinically efficacious inhibitor of HCV NS5B polymerase. , 2009, The Journal of organic chemistry.

[7]  N. Brown.  Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: Nucleoside analogues , 2009 .

[8]  D. Lavanchy,et al.  The global burden of hepatitis C , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[9]  M. Otto,et al.  The Mechanism of Action of β-d-2′-Deoxy-2′-Fluoro-2′-C-Methylcytidine Involves a Second Metabolic Pathway Leading to β-d-2′-Deoxy-2′-Fluoro-2′-C-Methyluridine 5′-Triphosphate, a Potent Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase , 2007, Antimicrobial Agents and Chemotherapy.

[10]  John Mao,et al.  Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine. , 2006, Journal of medicinal chemistry.

[11]  Guorong Chen,et al.  Synthesis and structure determination of the first 1′-C-cyano-β-D-nucleosides , 1993 .